Trial Profile
Safety and tolerability of fingolimod in patients with Relapsing-remitting multiple sclerosis (Canadian Gilenya® Go ProgramTM)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Jan 2017
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- 26 May 2015 New trial record